PanGen Biotech Inc. (KOSDAQ:222110)

Market Cap	67.98B -9.0%
Revenue (ttm)	13.71B -6.4%
Net Income	2.06B +28.0%
EPS	145.10 +7.6%
Shares Out	13.51M
PE Ratio	34.67
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,202
Open	5,120.00
Previous Close	5,110.00
Day's Range	4,855.00 - 5,150.00
52-Week Range	4,505.00 - 8,510.00
Beta	-0.10
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About PanGen Biotech

PanGen Biotech Inc. operates as a biologics company in South Korea. It develops biosimilar products, such as EPO, recombinant factor VIII, G-CSF, etc. The company also provides CHO cell lines for proteins and monoclonal antibodies; and one-stop services ranging from producer cell line development to GMP production. In addition, it offers reagents, quantitation kits, and cell based assay systems, as well as technology transfer service. PanGen Biotech Inc. was founded in 1999 and is based in Suwon-si, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 222110

Financial Performance

In 2025, PanGen Biotech's revenue was 13.42 billion, a decrease of -8.56% compared to the previous year's 14.67 billion. Earnings were 2.05 billion, an increase of 117.30%.